Queen’s awarded funding to develop new initiative to enhance life science sector and boost economy
UK Research and Innovation (UKRI) has announced today (11 August) that Queen’s University Belfast has been selected as one of 17 recipients to receive up to £50k each to lead development of a new regional research consortium.
The Northern Ireland Precision Biomarkers and Therapeutics Consortium (NIPBT) will aim to enhance collaboration of industry and academia across Northern Ireland within the Health and Life Sciences sector.
The NIPBT Consortium is one of 17 consortia projects funded by UKRI spread across the UK, including central and southern Scotland, south Wales, Northern Ireland, England’s north-west, north-east, south-east and the Midlands. Each project will build on local strengths in industry and research to create significant economic impact, drive local growth, provide skills training and create high-value jobs.
Each of the shortlisted projects has been awarded early-stage funding from the second wave of UKRI’s flagship Strength in Places Fund (SIPF). This funding will allow the consortia behind the projects, which involve universities, research organisations, businesses and local leadership, to develop their projects and apply for a further £10-50 million each from UKRI in late autumn this year.
The NIPBT will build on Northern Ireland’s existing strengths in digital health, diagnostics and pharmaceuticals and will bring together partners from industry and academia including; Almac Group, Fusion Antibodies, Sonrai Analytics, ProAxsis Limited, Diaceutics, and Exploristics to increase research, encourage innovation and make Northern Ireland’s life and health science sector more productive. It will develop new, more cost-effective targeted drugs and antibodies and new ways of diagnosing cancer and other conditions. The long-term aim is to attract and secure highly skilled jobs to the region to enhance its competitiveness and prosperity.
Commenting on the announcement, Professor Chris Scott, Director (Acting) from the Patrick G. Johnston Centre for Cancer Research at Queen’s University, said: "I am delighted with this news and to be given the opportunity to create a collaborative platform in Northern Ireland to exploit the potential of our health and life sciences sector, whilst making sure that we provide our own students with the key skills to realise high value jobs and opportunities here in Northern Ireland."
Professor Ian Greer, President and Vice-Chancellor at Queen’s University, said: "I am delighted Queen's has been awarded this grant from UK Research and Innovation to create The Northern Ireland Precision Biomarkers and Therapeutics Consortium. The Consortium is an excellent opportunity for us and our partners to bring together our collective knowledge and expertise and is an endorsement of the groundbreaking developments taking place in the life and health sciences sector in Northern Ireland.
"This Consortium has the potential to positively impact patient care by discovering new ways of diagnosing cancer and other conditions, both locally and globally, as well as driving growth in Northern Ireland through innovation and the development of skills to meet the needs of our economy."
Dr Robert Grundy, Interim CEO at Health Innovation Research Alliance Northern Ireland, said: "The award of this first phase of funding for the Northern Ireland Precision Biomarkers and Therapeutics Consortium is exciting and will act as a catalyst to exploit NI’s fundamental capabilities towards a significant engine driving diagnostic and therapeutic discoveries and innovation."
UKRI lead on the Strength in Places Fund, David Sweeney, said: “Strength in Places is a flagship fund for UKRI. We welcome the focus of the R&D Roadmap in unlocking economic opportunities around local economy in more places around the UK. I am delighted with the range of bids funded across the UK in the second wave of Strength in Places that will foster the local ecosystems to support innovation and sustained growth and strengthen collaboration between industry and our world-class research base.”